High prevalence of benign mammary tumors in a rat model of polycystic ovary syndrome during postmenopausal period

References

• Tehrani FR, Simbar M, Tohidi M, et al. The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. Reprod Biol Endocrinol. 2011;9:39.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270–284.
   PubMed Web of Science ®Google Scholar
• Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Ozkaya E, Cakir E, Cinar M, et al. Is hyperandrogenemia protective for fibrocystic breast disease in PCOS? Gynecol Endocrinol. 2012;28:468–471.
   PubMed Web of Science ®Google Scholar
• D'Amelio R, Farris M, Grande S, et al. Association between polycystic ovary and fibrocystic breast disease. Gynecol Obstet Invest. 2001;51:134–137.
   PubMed Web of Science ®Google Scholar
• Gumus II, Koktener A, Dogan D, et al. Polycystic ovary syndrome and fibrocystic breast disease: is there any association? Arch Gynecol Obstet. 2009;280:249–253.
   PubMed Web of Science ®Google Scholar
• Hartmann LC, Sellers TA, Frost MH, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353:229–237.
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867.
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale HF, Luque-Ramírez M, González F, Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011; 95:1048–1058.
   PubMed Web of Science ®Google Scholar
• González F, Rote NS, Minium J, et al. Evidence of proatherogenic inflammation in polycystic ovary syndrome. Metab Clin Exp. 2009;58:954–962.
   PubMed Web of Science ®Google Scholar
• Barthelmess EK, Naz RK. Polycystic ovary syndrome: current status and future perspective. Front Biosci (Elite Ed). 2014;6:104–119.
   PubMedGoogle Scholar
• Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327–1331.
   PubMed Web of Science ®Google Scholar
• Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748–758.
   PubMed Web of Science ®Google Scholar
• Somboonporn W, Davis SR. Postmenopausal testosterone therapy and breast cancer risk. Maturitas. 2004;49:267–275.
   PubMed Web of Science ®Google Scholar
• Ligibel J. Obesity and breast cancer. Oncology (Williston Park, N.Y.). 2011;25:994.
   PubMed Web of Science ®Google Scholar
• Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94:606–616.
   PubMed Web of Science ®Google Scholar
• Kaaks R, Rinaldi S, Key T, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12:1071–1082.
   PubMed Web of Science ®Google Scholar
• Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res. 1994;14:2113–2117.
   PubMed Web of Science ®Google Scholar
• Missmer SA, Eliassen AH, Barbieri RL, et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96:1856–1865.
   PubMed Web of Science ®Google Scholar
• Yeh S, Hu Y-C, Wang P-H, et al. Abnormal mammary gland development and growth retardation in female mice and MCF7 breast cancer cells lacking androgen receptor. J Exp Med. 2003;198:1899–1908.
   PubMed Web of Science ®Google Scholar
• Von Schoultz B. Androgens and the breast. Maturitas. 2007;57:47–49.
   PubMed Web of Science ®Google Scholar
• Scheen AJ, Beck ED, Flines J, et al. Obesity, insulin resistance and type 2 diabetes: risk factors for breast cancer. Rev Med Liege. 2011;66:238–244.
   PubMedGoogle Scholar
• Secreto G, Primi L. Androgens and *Benign Breast disease. Studies. 5:14–13.
   Google Scholar
• Lagiou P, Samoli E, Lagiou A, et al. A comparison of hormonal profiles between breast cancer and benign breast disease: a case-control study. Ann Oncol. 2013;24:2527–2533.
   PubMed Web of Science ®Google Scholar
• Zhu M-L, Kyprianou N. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J. 2010;24:769–777.
   PubMed Web of Science ®Google Scholar
• Wang X, Yin L, Rao P, et al. Targeted treatment of prostate cancer. J Cell Biochem. 2007;102:571–579.
   PubMed Web of Science ®Google Scholar
• Niu Y, Altuwaijri S, Yeh S, et al. Targeting the stromal androgen receptor in primary prostate tumors at earlier stages. Proc Natl Acad Sci USA. 2008;105:12188–12193.
   PubMed Web of Science ®Google Scholar
• Zhu M-L, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15:841–849.
   PubMed Web of Science ®Google Scholar
• Tehrani FR, Noroozzadeh M, Zahediasl S, et al. Introducing a rat model of prenatal androgen-induced polycystic ovary syndrome in adulthood. Exp Physiol. 2014;99:792–801.
   PubMed Web of Science ®Google Scholar
• Noroozzadeh M, Ramezani Tehrani F, Sedaghat K, et al. The impact of prenatal exposure to a single dose of testosterone on insulin resistance, glucose tolerance and lipid profile of female rat's offspring in adulthood. J Endocrinol Invest. 2015;38:489–495.
   PubMed Web of Science ®Google Scholar
• Volkovinskaya L, Fabrichnaya T, Pozharskaya A. Use of benzyl benzoate to obtain injection solutions of hormone preparations. Pharm Chem J. 1968;2:649.
   Google Scholar
• Fornes R, Maliqueo M, Hu M, et al. The effect of androgen excess on maternal metabolism, placental function and fetal growth in obese dams. Sci Rep. 2017;7:8066.
   PubMed Web of Science ®Google Scholar
• Kawaguchi H, Umekita Y, Souda M, et al. Increased bone mineral density in aged rats with spontaneous mammary dysplasia. In Vivo. 2007;21:583–586.
   PubMed Web of Science ®Google Scholar
• Marcondes F, Bianchi F, Tanno A. Determination of the estrous cycle phases of rats: some helpful considerations. Braz J Biol. 2002;62:609–614.
   PubMedGoogle Scholar
• Panaritis V, Despotidis P, Kyriakidis A. Diameter of mammary terminal ducts as an additional tool in evaluation of women with polycystic ovarium disease. Arch Gynecol Obstet. 2004;270:252–254.
   PubMedGoogle Scholar
• Samoli E, Trichopoulos D, Lagiou A, et al. The hormonal profile of benign breast disease. Br J Cancer. 2013;108:199–204.
   PubMed Web of Science ®Google Scholar
• Carlström K, Döberl A, Gershagen S, et al. Elevated peripheral levels of androgens and of some steroid sensitive plasma proteins in patients with severe fibrocystic breast disease: a preliminary report. Acta Obstet Gynecol Scand Suppl. 1984;63:157–158.
   Google Scholar
• Schairer C, Hill D, Sturgeon SR, et al. Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:1660–1665.
   PubMed Web of Science ®Google Scholar
• Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Lett. 2015;356:231–243.
   PubMed Web of Science ®Google Scholar
• Kahan Z, Gardi J, Nyari T, et al. Elevated levels of circulating insulin-like growth factor-I, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case-control study. Int J Oncol. 2006;29:193–200.
   PubMed Web of Science ®Google Scholar